GLOBAL HEV TESTING SYSTEM MARKET

INTRODUCTION

HEV antibody and HEV RNA detection are two of the frequently utilised assays for HEV infection. IgG anti-HEV antibodies indicate either recent or remote exposure, whereas IgM anti-HEV antibodies can be found in the first few months following HEV infection.

HEV RNA is a sign of active infection, whether it is acute or chronic. Although there are a number of diagnostic assays for anti-HEV antibodies, they have undergone relatively little testing and frequently give inconsistent results, especially for IgG antibodies.

As a result, even while the use of the existing antibody assays for case diagnosis in regions with high disease endemicity and for seroprevalence studies is troublesome, their use for case diagnosis in regions with low disease endemicity is still a challenge.

In underdeveloped nations, enterically transmitted acute hepatitis is frequently brought on by hepatitis E, which is brought on by infection with the hepatitis E virus (HEV).

Over the past ten years, wealthy nations have seen an increase in the recognition of sporadic hepatitis E cases.

GLOBAL HEV TESTING SYSTEM MARKET SIZE AND FORECAST

The Global HEV Testing SystemMarket accountedfor $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.

RECENT DEVELOPMENT

Using a variety of plasma samples that included HEV, it was determined how well hepatitis E virus (HEV) RNA nucleic acid amplification (NAT)-based assays performed.

The panel included 22 HEV-positive plasma samples from blood donors that represented 10-fold serial dilutions of the HEV genotypes 3a, 3b, 3f, and 4c.

There were two plasma samples used as a negative control. Every sample was blinded. Participants received the plasma samples, which had been produced as liquid or frozen materials, on dry ice.

Laboratories were asked to test the panel using their standard HEV assays, rate samples as positive or negative, and, if they so choose, return data for HEV RNA.

. In contrast to cases in underdeveloped nations, these cases frequently afflict persons with weakened immune systems, may be caused by zoonotic transmission, and occasionally result in permanent HEV infection.

The discovery of specific anti-HEV immunoglobulin M (IgM) antibodies to the virus in a person's blood is typically sufficient in regions where the disease is prevalent for the diagnosis of hepatitis E infection. For field use, rapid testing is available.

COMPANY PROFILE

• L&T 
• Agilent Technologies
• Reliance
• Mahindra
• Amara Raja

THIS REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many HEV Testing Systems are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global HEV Testing System and key vendor selection criteria
3. Where is the HEV Testing System manufactured? What is the average margin per unit?
4. Market share of Global HEV Testing System market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global HEV Testing System in-house
6. key predictions for next 5 years in Global HEV Testing System market
7. Average B-2-B HEV Testing System market price in all segments
8. Latest trends in HEV Testing System market, by every market segment
9. The market size (both volume and value) of the HEV Testing System market in 2023-2030 and every year in between?
10. Production breakup of HEV Testing System market, by suppliers and their OEM relationship